120 related articles for article (PubMed ID: 7951583)
1. Specific PCR amplification for N-ras mutations in neoplastic thyroid diseases.
Kaihara M; Taniyama M; Tadatomo J; Tobe T; Tomita M; Ito K; Ban Y; Katagiri T
Endocr J; 1994 Jun; 41(3):301-8. PubMed ID: 7951583
[TBL] [Abstract][Full Text] [Related]
2. [Specific amplification by PCR for N-ras mutation in thyroid follicular cartinoma].
Taniyama M; Kaihara M
Nihon Rinsho; 1994 Apr; 52(4):1075-80. PubMed ID: 8196166
[TBL] [Abstract][Full Text] [Related]
3. Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan.
Liu RT; Hou CY; You HL; Huang CC; Hock-Liew ; Chou FF; Wang PW; Cheng JT
Thyroid; 2004 Aug; 14(8):616-21. PubMed ID: 15320975
[TBL] [Abstract][Full Text] [Related]
4. N-ras mutation of thyroid tumor with special reference to the follicular type.
Oyama T; Suzuki T; Hara F; Iino Y; Ishida T; Sakamoto A; Nakajima T
Pathol Int; 1995 Jan; 45(1):45-50. PubMed ID: 7704243
[TBL] [Abstract][Full Text] [Related]
5. H-ras protooncogene mutations in human thyroid neoplasms.
Namba H; Gutman RA; Matsuo K; Alvarez A; Fagin JA
J Clin Endocrinol Metab; 1990 Jul; 71(1):223-9. PubMed ID: 2196280
[TBL] [Abstract][Full Text] [Related]
6. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis.
Namba H; Rubin SA; Fagin JA
Mol Endocrinol; 1990 Oct; 4(10):1474-9. PubMed ID: 2283998
[TBL] [Abstract][Full Text] [Related]
7. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas.
Manenti G; Pilotti S; Re FC; Della Porta G; Pierotti MA
Eur J Cancer; 1994; 30A(7):987-93. PubMed ID: 7946598
[TBL] [Abstract][Full Text] [Related]
8. Variability of Ha-ras (codon 12) proto-oncogene mutations in diverse thyroid cancers.
Bouras M; Bertholon J; Dutrieux-Berger N; Parvaz P; Paulin C; Revol A
Eur J Endocrinol; 1998 Aug; 139(2):209-16. PubMed ID: 9724079
[TBL] [Abstract][Full Text] [Related]
9. Specific pattern of RAS oncogene mutations in follicular thyroid tumors.
Vasko V; Ferrand M; Di Cristofaro J; Carayon P; Henry JF; de Micco C
J Clin Endocrinol Metab; 2003 Jun; 88(6):2745-52. PubMed ID: 12788883
[TBL] [Abstract][Full Text] [Related]
10. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.
Nikiforova MN; Lynch RA; Biddinger PW; Alexander EK; Dorn GW; Tallini G; Kroll TG; Nikiforov YE
J Clin Endocrinol Metab; 2003 May; 88(5):2318-26. PubMed ID: 12727991
[TBL] [Abstract][Full Text] [Related]
11. Point mutations of ras and Gs alpha subunit genes in thyroid tumors.
Horie H; Yokogoshi Y; Tsuyuguchi M; Saito S
Jpn J Cancer Res; 1995 Aug; 86(8):737-42. PubMed ID: 7559096
[TBL] [Abstract][Full Text] [Related]
12. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort.
Fukahori M; Yoshida A; Hayashi H; Yoshihara M; Matsukuma S; Sakuma Y; Koizume S; Okamoto N; Kondo T; Masuda M; Miyagi Y
Thyroid; 2012 Jul; 22(7):683-9. PubMed ID: 22650231
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Ras mutations in thyroid neoplasia.
Esapa CT; Johnson SJ; Kendall-Taylor P; Lennard TW; Harris PE
Clin Endocrinol (Oxf); 1999 Apr; 50(4):529-35. PubMed ID: 10468914
[TBL] [Abstract][Full Text] [Related]
14. Ha-ras oncogene (codon 12) mutation in thyroid carcinogenesis: analysis of 60 benign and malignant thyroid tumors.
Bouras M; Parvaz P; Berger N; Paulin C; Revol A
Ann Biol Clin (Paris); 1995; 53(10-11):549-55. PubMed ID: 8787281
[TBL] [Abstract][Full Text] [Related]
15. The natural protein kinase C alpha mutant is present in human thyroid neoplasms.
Prévostel C; Alvaro V; de Boisvilliers F; Martin A; Jaffiol C; Joubert D
Oncogene; 1995 Aug; 11(4):669-74. PubMed ID: 7651730
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.
Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA
Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of activating ras mutations in morphologically characterized thyroid nodules.
Ezzat S; Zheng L; Kolenda J; Safarian A; Freeman JL; Asa SL
Thyroid; 1996 Oct; 6(5):409-16. PubMed ID: 8936664
[TBL] [Abstract][Full Text] [Related]
18. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression.
Basolo F; Pisaturo F; Pollina LE; Fontanini G; Elisei R; Molinaro E; Iacconi P; Miccoli P; Pacini F
Thyroid; 2000 Jan; 10(1):19-23. PubMed ID: 10691309
[TBL] [Abstract][Full Text] [Related]
19. Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction-fragment-length polymorphism analysis from paraffin-embedded tissues.
Capella G; Matias-Guiu X; Ampudia X; de Leiva A; Perucho M; Prat J
Diagn Mol Pathol; 1996 Mar; 5(1):45-52. PubMed ID: 8919545
[TBL] [Abstract][Full Text] [Related]
20. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]